I WISH YOU A NICE WEEKEND
1. ANNUAL BOOSTERS The US FDA has authorized second booster, or fourth, doses for parts of the US population, raising questions over how frequently boosters will be required moving forward. Several companies, including Novavax and Moderna, have begun initiatives to develop joint influenza and COVID-19 shots, creating what would be a new annual vaccine administered each fall. But several US scientists and researchers recently urged more involved dialogue regarding future plans for the use of SARS-CoV-2 vaccine boosters, pushing back on the idea of annual boosters and calling for more data on the value of annual SARS-CoV-2 booster doses. While there is no evidence suggesting any harm from additional booster doses, the experts have shared several concerns that could stem from a policy requiring annual vaccinations. First, they worry that an emphasis on boosters diminishes the long-lasting protection that current vaccine doses provide against severe COVID-19 disease. Second, experts worry that a lack of evidence in regulatory decision making could set a dangerous precedent moving forward. The group specifically urged the FDA to measure T-cell responses, in addition to antibody responses, when conducting SARS-CoV-2 vaccine trials. Lastly, they noted the lack of response for both first and second booster doses signals fatigue from the US public. More than 100 million US residents have received the first COVID-19 booster, roughly 50% of eligible people. Some worry that “booster fatigue” will be a problem, adding to calls for a more prudent, data-driven approach to annual boosters.
FROM THE WASHINGTON POST:
Vaccines for young kids could be available as soon as June, FDA official says
GIVE US YOUR FEEDBACK. CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.
Click here to submit feedback. Let us know what you think.
Click here to go to the iExposed.us youtube channel
Click here to go to the iExposed.us website
P.O. Box 721